3,6'-Dithiothalidomide is primarily investigated for its potential therapeutic applications in the field of oncology and immunology. It has shown promise as an anti-cancer agent due to its ability to inhibit angiogenesis, the process by which new blood vessels form, thereby restricting the blood supply to tumors and limiting their growth. Additionally, it exhibits immunomodulatory properties, making it a candidate for treating autoimmune diseases by regulating the immune response. Research is ongoing to explore its efficacy in targeting specific cancer types and its role in combination therapies to enhance treatment outcomes. Its mechanism of action involves modulating key signaling pathways, which may also contribute to its anti-inflammatory effects.